GWAS and EWAS in Patients With Erdheim-Chester Disease

Launched by AUGUSTO VAGLIO · Mar 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying Erdheim-Chester Disease (ECD), a rare condition where certain blood cells called histiocytes grow uncontrollably and can damage various organs in the body. Researchers want to learn more about the genetic factors that may make someone more likely to develop ECD. They will analyze the DNA of patients with ECD and compare it to healthy individuals to find any differences that could help explain why some people get this disease and others don’t. Understanding these genetic markers could lead to new treatments in the future.

To join the study, participants need to have a confirmed diagnosis of ECD through a tissue sample. Unfortunately, people who have already received treatment for the disease will not be eligible to participate. Those who take part can expect to provide samples for genetic analysis and contribute to important research that may improve understanding and treatment of ECD. The trial is currently recruiting participants of all ages, so if you or someone you know has ECD and is interested, this could be a valuable opportunity to help advance medical knowledge about the disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - ECD with histological confirmation of disease
• Exclusion criteria:
• • - previously treated patients (for methylation and gene expression)